Treatment approved for advanced Hodgkin lymphoma
Adults with advanced Hodgkin lymphoma have access to a new treatment, after the National Institute for Health and Care Excellence has recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use. Around 800 people annually with previously untreated stage 3 or 4 CD30-positive Hodgkin lymphoma could benefit from this treatment, which combines brentuximab vedotin with doxorubicin, dacarbazine and vinblastine.